GQ Bio Therapeutics GmbH

General information
GQ Bio Therapeutics GmbH
Ballindamm 39
20095 Hamburg, Hamburg
Germany

Contact person: Kilian Guse, Chief Executive Officer, Co-Founder
Company main phone: +49 (40) 999993026
Company main fax:  +49 (40) 999993332
Website:  https://gq-biotx.com/
Year founded:2012
Source of foundation:Independent foundation
No. of employees: Worldwide:  16
Corporate description / mission:
GQ Bio Therapeutics GmbH is a biotech company that develops gene therapy-based drugs to treat chronic, prevalent diseases such as osteoarthritis and intervertebral disc degeneration. The company's product GQ-501 is a helper-dependent adenoviral vector expressing proteoglycan 4 (also known as lubricin) and interleukin-1 receptor antagonist (IL-1Ra), and is being developed for osteoarthritis. The company's another product GQ-401 is a helper-dependent adenoviral gene therapy vector expressing an undisclosed therapeutic protein, which is being developed for treatment of intervertebral disc degeneration.
State of ownership: Private / independent
Headquarters: HQ: Yes
Remarks on ownership / listings
Formerly known as GeneQuine Biotherapeutics GmbH
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Gene therapy
Primary therapeutic areas:
  • Musculoskeletal system and connective tissue / Orthopedics
Business model:
  • Out-licensing
  • R&D
Customer segments:
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:2
Description of products:
GQ-501
GQ-401
GQ-203/PCRX201 Acquired by Pacira Biosciences
Technology used:
HCAd Vector Platform
Financing details
Financing details:
The company started operations with a seed investment by High-Tech Gründerfonds and Innovationsstarter Fonds Hamburg.
Collaborations & Clients
Partnering strategy / collaborations:
Pacira
Exothera
Baylor College Of Medicine
mSKIL
© 2026 Biotechgate by Venture Valuation
X